Zura Bio Adds Seasoned Immunology Executives to Board Amid Phase 2 Advancements
Event summary
- Zura Bio appointed Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors on February 21, 2026.
- Neil Graham, M.B.B.S., M.D., M.P.H., stepped down from the Board on the same date.
- Eisner is EVP and Chief Medical Officer at Vir Biotechnology; Nirula is EVP and Head of R&D at Recludix Pharma.
- Nirula previously led tibulizumab’s development at Eli Lilly before its licensing to Zura.
- Zura is advancing Phase 2 trials for tibulizumab in hidradenitis suppurativa and systemic sclerosis.
The big picture
Zura Bio’s board additions reflect a strategic pivot toward deepening immunology expertise as it navigates Phase 2 trials. The appointments come amid a competitive landscape where dual-pathway antibody development is gaining traction. Eisner and Nirula’s combined experience in global regulatory submissions and commercialization could be pivotal as Zura seeks to differentiate its pipeline in autoimmune and inflammatory diseases.
What we're watching
- Pipeline Momentum
- Whether Zura can leverage Eisner and Nirula’s expertise to accelerate Phase 2 readouts for tibulizumab.
- Strategic Alignment
- How the new directors’ immunology backgrounds will shape Zura’s dual-pathway antibody strategy.
- Governance Impact
- The pace at which the board refresh could influence investor confidence amid clinical-stage transitions.
Related topics